LGVN Stock — Longeveron Inc.: Cash, EV, Pipeline

What they do

Our lead investigational product candidate is laromestrocel, also referred to as Lomecel-B ® . Laromestrocel is a proprietary, scalable, allogeneic cellular therapy that has multiple potential modes of action that include pro-vascular, pro-regenerative, and anti-inflammatory mechanisms that collectively appear to promote tissue repair and healing.

Source: 10-K FY2025 via SEC EDGAR

Share price

$1.81

Market cap

$5.8M

Cash

$10.1M

Enterprise value

-$4.3M

Balance sheet

Cash	$10.1M
Debt	$0.0M
Net cash	$10.1M
Enterprise value	-$4.3M
Basic shares	30.4M shares
Fully diluted shares	77.3M shares
Fully diluted market cap	$139.8M
Cash per share	$0.33
Quarterly burn	$5.7M
Cash runway	1.8 quarters

Cash figures as of 2026-06-30. Database snapshot: 2026-11-07.

Share structure

Common

30.4M

Pre-funded warrants

0.0M

Options

0.8M

RSUs

2.6M

Warrants

21.2M

Converts

0.0M

Conv preferred

22.2M

ESPP reserve

—

FDSO

77.3M

Cap table as of 2026-06-30.

Price history

Loading LGVN daily closes…

Loading price history…

Recently reported

laromestrocel Phase 2 Mixed · 2026-10-26

hypoplastic left heart syndrome

Primary: Change from baseline in right ventricular ejection fraction (RVEF) at Month 12 in the ELPIS II Phase 2b trial of laromestrocel in hypoplastic left heart syndrome (HLHS) — Did not meet the primary endpoint: mean RVEF decreased by 3.3 (SD=8.4) percentage points in the laromestrocel group and 2.6 (SD=10.5) in the standard of care group (baseline adjusted difference=-1.36, 95% CI: -8.0 - 6.7, p=0.68)

· Pre-specified secondary clinical outcome endpoint major adverse cardiac events (MACE) achieved statistical significance: 8 events in the standard of care arm versus 1 in the laromestrocel treatment arm (P=0.043)

· 40 randomized infants in the intention-to-treat population; baseline and Month 12 CMR available for 28 infants (15 standard of care, 13 laromestrocel)

· Company intends to request a meeting with the FDA to review the results and determine potential next steps

· Results selected for the Late-Breaking Science Program podium presentation at the AHA 2026 Scientific Sessions

Safety: Favorable safety and tolerability profile through 12 months, with no treatment-related serious adverse events identified

Source release →

Upcoming catalysts

No upcoming catalysts on file for this company.

Full readout calendar →

Pipeline assets

laromestrocel

Phase 2 · Active Modality: cell therapy (allogeneic mesenchymal stem cells)

Aliases Lomecel-B

Partnerships University of Miami (exclusive worldwide license for Aging-related Frailty MSC technology)

Indications

hypoplastic left heart syndrome (HLHS) (Phase 2)
Alzheimer's disease (Phase 2)
pediatric dilated cardiomyopathy (DCM) (Stage not disclosed)
Aging-related Frailty (Stage not disclosed)

Catalysts

— not dated

Status note Lead and only investigational product candidate. ELPIS II: multicenter randomized double-blind controlled Phase 2b trial of laromestrocel as adjunct to second-stage HLHS heart reconstructive surgery (next step after completed 10-patient open-label Phase 1 ELPIS I). A second financing closing is contingent on ELPIS II Phase 2b results demonstrating statistical significance of agreed primary endpoints. AD: following March 2025 Type B FDA meeting, company seeks partnership/non-dilutive funding for proposed single seamless adaptive Phase 2/3. Pediatric DCM and Aging-related Frailty: in clinical development per filing, phases not stated in excerpts.

Per-asset detail extracted from the 10-Q filed 2026-08-12. Fields the filing does not state are marked "not disclosed" rather than filled from other sources.

Pipeline

Lead drug	Lomecel-B medicinal signaling cells
Lead indication	Hypoplastic Left Heart Syndrome
Lead phase	Phase 2
Active trials	1

Active clinical trials

Trial	Phase	Status	Role	Sponsor	BP	Condition(s)	Mgmt guide
NCT04925024	Phase 2	Active, not recruiting	Sponsor	LGVN	—	Hypoplastic Left Heart Syndrome	—

Sponsor-matched active trials from ClinicalTrials.gov (1 as sponsor, 0 as collaborator); "Sponsor" = company is the lead sponsor, "Collaborator" = company is a collaborator. The BP column flags big-pharma involvement as lead sponsor or collaborator (excluding the company itself). The Mgmt guide column shows what management guided for readout timing when a guided program matches the trial (hover for the quote, click for the source). Trial listings are not a company pipeline slide.

View all 1 active trials for Longeveron Inc. on ClinicalTrials.gov

Specialist fund holders

Tracked specialist funds: ADAR1 Capital Management, Aisling Capital, Ally Bridge Group, Avoro Capital Advisors, BVF Partners, Baker Bros. Advisors, Boxer Capital, Braidwell LP, Casdin Capital, Cormorant Asset Management, DAFNA Capital, Deerfield Management, EcoR1 Capital, Frazier Life Sciences, Great Point Partners, Ikarian Capital, Logos Global Management, OrbiMed Advisors, Perceptive Advisors, RA Capital Management, RTW Investments, Sphera Biotech, Stonepine Capital, Tang Capital Partners, Vivo Capital.

Fund	Shares	Q/Q change	% of portfolio	Filing
Logos Global Management	1,287,000	+1,287,000	0.04%	2026-08-14
ADAR1 Capital Management	108,406	-91,594	0.00%	2026-08-14

Specialist-fund positions from 13F filings. Q/Q change is vs the prior quarter's filing; % of portfolio is the fund's own reported portfolio weight.

Latest news

Loading headlines…

Headlines from the Fully Diluted live wire: IR newsrooms, newswires, SEC filings, and halt notices, refreshed every 15 minutes.

LGVN — Longeveron Inc. ☆